BioMarin Pharmaceutical Inc.
Common Stock · USD · NASDAQ
Price
$52.6
Cap
—
Earnings
—
30d Trend
-1.6%
30% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 53×Macro 0.99 (−1%)=52
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
Potential value play — but fundamentals need strengthening
BRAIN47'S ASSESSMENT
I rate BioMarin Pharmaceutical Inc. at 52/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is quality at 62/100. I classify this as a growth position with the strongest thesis on a long-term horizon.
PAST PERFORMANCE
1 MONTH
-1.7%
3 MONTHS
-15.1%
12 MONTHS
-9.8%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
Potential value play — but fundamentals need strengthening. Quality (62) and Fundamentals (60) are the primary strengths. I note that momentum is the weakest area at 42/100 — this warrants monitoring. Historical volatility is moderate at 30%. I classify this as a growth position — positive trend direction combined with solid fundamentals points to capital appreciation.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.